KRAS mutations in lung cancer

Clinical Lung Cancer

Volumn 14, Issue 3, 2013, Pages 205-214

  Karachaliou, Niki ^a   Mayo, Clara ^a   Costa, Carlota ^a   Magrí, Ignacio ^a   Gimenez Capitan, Ana ^a   Molina Vila, Miguel Angel ^a   Rosell, Rafael ^a,b  

^a INSTITUT UNIVERSITARI DEXEUS   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Aadenocarcinoma; Epidermal growth factor receptor; KRAS mutations; Non small cell lung cancer

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; BEVACIZUMAB; BEXAROTENE; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NEUROFIBROMIN; PACLITAXEL; PANITUMUMAB; PEMETREXED; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; RAPAMYCIN; RING FINGER PROTEIN; RNA BINDING PROTEIN; SELUMETINIB; SHORT HAIRPIN RNA; SORAFENIB; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR GATA 2; VANDETANIB; WT1 PROTEIN;

ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; COLORECTAL CANCER; ENZYME ACTIVITY; ETHNICITY; HISTOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; TOBACCO;

ADENOCARCINOMA; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84879919632     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2012.09.007     Document Type: Review

References (89)

1. G.J. Riely, J. Marks, W. Pao KRAS mutations in non-small cell lung cancer Proc Am Thorac Soc 6 2009 201 205
2. J.L. Bos Ras oncogenes in human cancer: a review Cancer Res 49 1989 4682 4689
3. M.S. Brose, P. Volpe, M. Feldman BRAF and RAS mutations in human lung cancer and melanoma Cancer Res 62 2002 6997 7000
4. M. Trahey, F. McCormick A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants Science 238 1987 542 545
5. H. Shigematsu, L. Lin, T. Takahashi Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers J Natl Cancer Inst 97 2005 339 346
6. T. Kosaka, Y. Yatabe, H. Endoh Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications Cancer Res 64 2004 8919 8923
7. M. Taron, Y. Ichinose, R. Rosell Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas Clin Cancer Res 11 2005 5878 5885
8. K. Okudela, T. Woo, H. Kitamura KRAS gene mutations in lung cancer: particulars established and issues unresolved Pathol Int 60 2010 651 660
9. P.J. Roberts, T.E. Stinchcombe, C.J. Der Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol 28 2010 4769 4777
10. K.L. Thu, E.A. Vucic, R. Chari Lung adenocarcinoma of never smokers and smokers harbor differential regions of genetic alteration and exhibit different levels of genomic instability PLoS ONE 7 2012 e33003
11. C. Mao, L.X. Qiu, R.Y. Liao KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies Lung Cancer 69 2010 272 278
12. F. Le Calvez, A. Mukeria, J.D. Hunt TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers Cancer Res 65 2005 5076 5083
13. G.J. Riely, M.G. Kris, D. Rosenbaum Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma Clin Cancer Res 14 2008 5731 5734
14. S.L. Graziano, G.P. Gamble, N.B. Newman Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer J Clin Oncol 17 1999 668 675
15. P. Keohavong, M.A. DeMichele, A.C. Melacrinos Detection of K-ras mutations in lung carcinomas: relationship to prognosis Clin Cancer Res 2 1996 411 418
16. C. Lu, J.C. Soria, X. Tang Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers J Clin Oncol 22 2004 4575 4583
17. R.J. Slebos, R.E. Kibbelaar, O. Dalesio K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung N Engl J Med 323 1990 561 565
18. Y. Fukuyama, T. Mitsudomi, K. Sugio K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer Br J Cancer 75 1997 1125 1130
19. C.L. Huang, T. Taki, M. Adachi Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer Int J Oncol 12 1998 553 563
20. M. Miyake, M. Adachi, C. Huang A novel molecular staging protocol for non-small cell lung cancer Oncogene 18 1999 2397 2404
21. H.H. Nelson, D.C. Christiani, E.J. Mark Implications and prognostic value of K-ras mutation for early-stage lung cancer in women J Natl Cancer Inst 91 1999 2032 2038
22. C. Mascaux, N. Iannino, B. Martin The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis Br J Cancer 92 2005 131 139
23. V.D. Cataldo, D.L. Gibbons, R. Pérez-Soler Treatment of non-small-cell lung cancer with erlotinib or gefitinib N Engl J Med 364 2011 947 955
24. M. Fukuoka, Y.L. Wu, S. Thongprasert Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) J Clin Oncol 29 2011 2866 2874
25. T.S. Mok, Y.L. Wu, S. Thongprasert Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
26. T. Mitsudomi, S. Morita, Y. Yatabe Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 2010 121 128
27. M. Maemondo, A. Inoue, K. Kobayashi Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2010 2380 2388
28. R. Rosell, E. Carcereny, R. Gervais Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 2012 239 246
29. C. Zhou, Y.L. Wu, G. Chen Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 12 2011 735 742
30. C. Mayo, J. Bertran-Alamillo, M.A. Molina-Vila Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications Pharmacogenomics 13 2012 789 802
31. H. Linardou, I.J. Dahabreh, D. Kanaloupiti Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer Lancet Oncol 9 2008 962 972
32. C.S. Karapetis, S. Khambata-Ford, D.J. Jonker K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 2008 1757 1765
33. A. Lièvre, J.B. Bachet, V. Boige KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab J Clin Oncol 26 2008 374 379
34. M. Hamilton, J.L. Wolf, J. Rusk Effects of smoking on the pharmacokinetics of erlotinib Clin Cancer Res 12 2006 2166 2171
35. F. Cappuzzo, T. Ciuleanu, L. Stelmakh Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study Lancet Oncol 11 2010 521 529
36. V.A. Miller, P. O'Connor, C. Soh A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) J Clin Oncol 27 2009 abstract LBA8002
37. E.S. Kim, V. Hirsh, T. Mok Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial Lancet 372 2008 1809 1818
38. T. Winton, R. Livingston, D. Johnson Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer N Engl J Med 352 2005 2589 2597
39. F.A. Shepherd, A. Bourredjem, E. Brambilla Prognostic and predictive effects of KRAS mutation subtype in completely resected non-small cell lung cancer (NSCLC): A LACE-bio study J Clin Oncol 30 suppl 2012 abstr 7007
40. C. Camps, E. Jantus-Lewintre, A. Cabrera The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients Lung Cancer 72 2011 365 369
41. A. Kalikaki, A. Koutsopoulos, D. Hatzidaki Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status Lung Cancer 69 2010 110 115
42. N.T. Ihle, L.A. Byers, E.S. Kim Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome J Natl Cancer Inst 104 2012 228 239
43. E.S. Kim, R.S. Herbst, I.I. Wistuba The BATTLE trial: personalizing therapy for lung cancer Cancer Discov 1 2011 44 53
44. M.C. Garassino, M. Marabese, P. Rusconi Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer Ann Oncol 22 2011 235 237
45. J.A. Engelman, L. Chen, X. Tan Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers Nat Med 14 2008 1351 1356
46. Q.B. She, D.B. Solit, Q. Ye The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells Cancer Cell 8 2005 287 297
47. I.K. Mellinghoff, M.Y. Wang, I. Vivanco Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors N Engl J Med 353 2005 2012 2024
48. J.A. Engelman The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung cancer Clin Cancer Res 13 2007 s4637 s4640
49. S.V. Sharma, M.A. Fischbach, D.A. Haber 'Oncogenic shock': explaining oncogene addiction through differential signal attenuation Clin Cancer Res 12 2006 4392s 4395s
50. P.A. Janne, A. Tsang Shaw, J. Rodrigues Pereira Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as secondline treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC) J Clin Oncol 30 suppl 2012 abstr 7503, ASCO 2012
51. C.L. Mahoney, B. Choudhury, H. Davies LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition Br J Cancer 100 2009 370 375
52. L. Ding, G. Getz, D.A. Wheeler Somatic mutations affect key pathways in lung adenocarcinoma Nature 455 2008 1069 1075
53. L. Makowski, D.N. Hayes Role of LKB1 in lung cancer development Br J Cancer 99 2008 683 688
54. C.M. Johannessen, B.W. Johnson, S.M. Williams TORC1 is essential for NF1-associated malignancies Curr Biol 18 2008 56 62
55. S. Vicent, R. Chen, L.C. Sayles Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models J Clin Invest 120 2010 3940 3952
56. J.L. Hanson, N.A. Hawke, D. Kashatus The nuclear factor kappa B subunits RelA/p65 and c-Rel potentiate but are not required for Ras-induced cellular transformation Cancer Res 64 2004 7248 7255
57. E. Pikarsky, R.M. Porat, I. Stein NF-kappaB functions as a tumour promoter in inflammation-associated cancer Nature 431 2004 461 466
58. T.S. Finco, J.K. Westwick, J.L. Norris Oncogenic Ha-Ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation J Biol Chem 272 1997 24113 24116
59. W.C. Huang, T.K. Ju, M.C. Hung Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB Mol Cell 26 2007 75 87
60. K. Kawauchi, K. Araki, K. Tobiume p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation Nat Cell Biol 10 2008 611 618
61. K. Kawauchi, K. Araki, K. Tobiume Loss of p53 enhances catalytic activity of IKKbeta through O-linked beta-N-acetyl glucosamine modification Proc Natl Acad Sci U S A 106 2009 3431 3436
62. E. Meylan, A.L. Dooley, D.M. Feldser Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma Nature 462 2009 104 107
63. J. Luo, M.J. Emanuele, D. Li A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene Cell 137 2009 835 848
64. D.A. Barbie, P. Tamayo, J.S. Boehm Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 Nature 462 2009 108 112
65. M.S. Kumar, D.C. Hancock, M. Molina-Arcas The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer Cell 149 2012 642 655
66. J.A. Simon, C.A. Lange Roles of the EZH2 histone methyltransferase in cancer epigenetics Mutat Res 647 2008 21 29
67. M. Santarpia, I. Magri, M. Sanchez-Ronco mRNA expression levels and genetic status of genes involved in the EGFR and NF-kappaB pathways in metastatic non-small-cell lung cancer patients J Transl Med 9 2011 163
68. Huqun, R. Ishikawa, J. Zhang Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer Cancer 118 2012 1599 1606
69. J. Min, A. Zaslavsky, G. Fedele An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB Nat Med 16 2010 286 294
70. J. Mallen-St Clair, R. Soydaner-Azeloglu, K.E. Lee EZH2 couples pancreatic regeneration to neoplastic progression Genes Dev 26 2012 439 444
71. C.M. House, A. Möller, D.D. Bowtell Siah proteins: novel drug targets in the Ras and hypoxia pathways Cancer Res 69 2009 8835 8838
72. A.U. Ahmed, R.L. Schmidt, C.H. Park Effect of disrupting seven-in-absentia homolog 2 function on lung cancer cell growth J Natl Cancer Inst 100 2008 1606 1629
73. R.L. Schmidt, C.H. Park, A.U. Ahmed Inhibition of RAS-mediated transformation and tumorigenesis by targeting the downstream E3 ubiquitin ligase seven in absentia homologue Cancer Res 67 2007 11798 11810
74. R.J. Nadeau, J.L. Toher, X. Yang Regulation of Sprouty2 stability by mammalian Seven-in-Absentia homolog 2 J Cell Biochem 100 2007 151 160
75. M.H. Wei, F. Latif, S. Bader Construction of a 600-kilobase cosmid clone contig and generation of a transcriptional map surrounding the lung cancer tumor suppressor gene (TSG) locus on human chromosome 3p21.3: progress toward the isolation of a lung cancer TSG Cancer Res 56 1996 1487 1492
76. J.J. Oh, A. Razfar, I. Delgado 3p21.3 tumor suppressor gene; H37/Luca15/RBM5 inhibits growth of human lung cancer cells through cell cycle arrest and apoptosis Cancer Res 66 2006 3419 3427
77. L. Ji, J.D. Minna, J.A. Roth 3p21.3 tumor suppressor cluster: prospects for translational applications Future Oncol 1 2005 79 92
78. L.C. Sutherland, K. Wang, A.G. Robinson RBM5 as a putative tumor suppressor gene for lung cancer J Thorac Oncol 5 2010 294 298
79. H. Edamatsu, Y. Kaziro, H. Itoh LUCA15, a putative tumour suppressor gene encoding an RNA-binding nuclear protein, is down-regulated in ras-transformed rat-1 cells Genes Cells 5 2000 849 858
80. H. Liang, J. Zhang, C. Shao Differential expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues J Exp Clin Cancer Res 31 2012 36
81. F. Luppi, A.M. Longo, W.I. de Boer Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation Lung Cancer 56 2007 25 33
82. N. Sunaga, H. Imai, K. Shimizu Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer Int J Cancer 130 2012 1733 1744
83. M. Collado, M. Serrano Senescence in tumours: evidence from mice and humans Nat Rev Cancer 10 2010 51 57
84. S. Ansieau, J. Bastid, A. Doreau Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence Cancer Cell 14 2008 79 89
85. P.T. Tran, E.H. Shroff, T.F. Burns Twist1 suppresses senescence programs and thereby accelerates and maintains mutant kras-induced lung tumorigenesis PLoS Genet 8 2012 e1002650
86. L. Soucek, J. Whitfield, C.P. Martins Modelling Myc inhibition as a cancer therapy Nature 455 2008 679 683
87. C. Scholl, S. Fröhling, I.F. Dunn Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells Cell 137 2009 821 834
88. C. Babij, Y. Zhang, R.J. Kurzeja STK33 kinase activity is nonessential in KRAS-dependent cancer cells Cancer Res 71 2011 5818 5826
89. M. Puyol, A. Martín, P. Dubus A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma Cancer Cell 18 2010 63 73